soul trial oral semaglutide cardiovascular outcomes 2024 and in Patients with Type 2 Diabetes oral semaglutide cardiovascular outcomes soul

A 2026 UCL study published in BMC Medicine found that around 1.6 million adults in England, Wales, and Scotland used a GLP-1 weight-loss drug in the year to early 2025

Medications like Wegovy are known as GLP-1 agonists, and many of these drugs were initially prescribed to manage Type 2 diabetes but have since gained popularity for helping patients manage weight

However, what happens when you decide to stop taking it

This 3-month window after transplant serves to mitigate reverse causality effects, ensuring that outcomes are more reliably attributed to the use of GLP-1RA

Its active compound, curcumin, can help reduce dark pigment by slowing melanin production 10